![](/img/cover-not-exists.png)
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C JVolume:
104
Year:
2010
Language:
english
Pages:
7
DOI:
10.1038/sj.bjc.6605972
File:
PDF, 527 KB
english, 2010